Georgia's Online Cancer Information Center

Lymphoma Clinical Trials in Georgia

Cancer Type = Lymphoma
Cancer Type = Lymphoma
There are currently 111 active Lymphoma clinical trials in Georgia.
1.
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01871727
Protocol IDs
E7777-G000-302
NCI-2013-00713
3.
NCORP Trial
A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).
Cancer Type
Lymphoma
NCI ID
NCT03575351
Protocol IDs
JCAR017-BCM-003
NCI-2018-02503
2018-000929-32
U1111-1213-1944
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
7.
A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma
NCI ID
NCT03458728
Protocol IDs
19176
NCI-2018-00809
2017-000383-15
8.
A Phase 1 / 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Non-Hodgkin's Lymphoma (NHL)
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT03740529
Protocol IDs
LOXO-BTK-18001
NCI-2019-02015
13.
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02732275
Protocol IDs
DS3201-A-J101
NCI-2019-00366
14.
NCORP Trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCI ID
NCT02730312
Protocol IDs
XmAb14045-01
NCI-2016-00916
15.
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03287908
Protocol IDs
20170122
NCI-2017-02084
2017-001997-41
16.
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
17.
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and / or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03274219
Protocol IDs
CRB-402
NCI-2017-01861
19.
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCI ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
20.
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Cancer Type
Lymphoma, Unknown Primary
NCI ID
NCT03726333
Protocol IDs
B7461009
NCI-2019-01060
HEPATIC IMPAIRMENT
lorlatinib HEPATIC IMPAIRMENT
21.
NCORP Trial
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03555955
Protocol IDs
CPX351-102
NCI-2019-00697
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
23.
NCORP Trial
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02631044
Protocol IDs
017001
NCI-2016-00057
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
25.
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03218683
Protocol IDs
D6910C00001
NCI-2017-01390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
34.
NCORP Trial
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03651128
Protocol IDs
BB2121-MM-003
NCI-2018-02057
U1111-1217-9988
2018-001023-38
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
36.
37.
A Phase I / II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03739619
Protocol IDs
Winship4388-18
NCI-2018-02221
IRB00104033
38.
A Phase I / II Study of Ixazomib and Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03323151
Protocol IDs
PrE0404
NCI-2017-02399
X16077
41.
A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03650491
Protocol IDs
FOR46-002
NCI-2018-02600
42.
A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT02992522
Protocol IDs
OSU-16187
NCI-2016-01723
2016C0150
45.
A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients with Untreated Mantle Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03872180
Protocol IDs
Winship4363-18
NCI-2018-00995
IRB00102827
56.
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03038672
Protocol IDs
10089
10089
NCI-2017-00120
MC168D
57.
A Randomized Phase I Dose-Escalation Trial of Carfilzomib with and without Romidepsin in Cutaneous T-Cell Lymphoma
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01738594
Protocol IDs
NU 12H06
NCI-2012-01952
IST-CAR-532
SP0021927
STU00071042
61.
NCORP Trial
A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
Cancer Type
Breast Cancer, Cervical Cancer, Lymphoma, Prostate Cancer
NCI ID
NCT03190291
Protocol IDs
WF-30917CD
WF-30917CD
WF-30917CD
NCI-2017-01840
Treatment Sites (1)
62.
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Cancer Type
Lymphoma
NCI ID
NCT02600897
Protocol IDs
NCT02600897
2015-001999-22
GO29834
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
64.
ACP 196 Alone or in Combination With Rituximab in Follicular Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT02180711
Protocol IDs
ACE-LY-003
NCI-2014-02238
68.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
70.
Consolidation and Maintenance Therapy with Carfilzomib, Pomalidomide and Dexamethasone (CPD) in High-Risk Myeloma Patients: A Phase 2 Study with a Safety Run-In
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03756896
Protocol IDs
Winship4101-17
NCI-2017-02052
IRB00097882
71.
Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)
Cancer Type
Lymphoma
NCI ID
NCT03204916
Protocol IDs
ACCL16N1CD
ACCL16N1CD
COG-ACCL16N1CD
NCI-2017-01053
72.
NCORP Trial NCI Priority
EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type
Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT02465060
Protocol IDs
EAY131
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Treatment Sites (29)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
73.
GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03320642
Protocol IDs
INCB 39110-119/GRAVITAS-119
NCI-2018-00119
76.
Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02670525
Protocol IDs
15-384
NCI-2016-00336
77.
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed / Refractory Multiple Myeloma Patients: A Phase 1b Trial
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03770260
Protocol IDs
10249
10249
NCI-2018-03121
78.
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCI ID
NCT03779854
Protocol IDs
RG1003345
NCI-2018-01752
9880
81.
Multi-Institution Phase I / Ib Study of Ibrutinib with ABT-199 in Relapsed / Refractory Mantle Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT02419560
Protocol IDs
17983
NCI-2017-02213
17983
82.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03698994
Protocol IDs
APEC1621J
APEC1621J
NCI-2018-02150
83.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1 / 2 / 3 / 4 Alterations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03210714
Protocol IDs
APEC1621B
APEC1621B
NCI-2017-01159
84.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03213704
Protocol IDs
APEC1621A
APEC1621A
NCI-2017-01264
APEC1621A
85.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03526250
Protocol IDs
APEC1621I
APEC1621I
NCI-2018-00863
86.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type
Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03213691
Protocol IDs
APEC1621E
APEC1621E
NCI-2017-01250
APEC1621E
87.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03233204
Protocol IDs
APEC1621H
APEC1621H
NCI-2017-00766
APEC1621H
88.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
Cancer Type
Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
NCI-2017-01243
APEC1621F
89.
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03213678
Protocol IDs
APEC1621D
APEC1621D
NCI-2017-01249
APEC1621D
90.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
92.
PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03605719
Protocol IDs
Winship4398-18
NCI-2018-01217
IRB00104234
93.
Phase 1 / 2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Cancer Type
Breast Cancer, Cervical Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
94.
Phase 1 / 2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03761108
Protocol IDs
R5458-ONC-1826
NCI-2019-02952
2018-003188-78
97.
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Cancer Type
Cervical Cancer, Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT02503423
Protocol IDs
ASTX660-01
NCI-2017-01760
99.
Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases from Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma, Unknown Primary
NCI ID
NCT03858205
Protocol IDs
16M-18-2
NCI-2018-03600
101.
102.
Pilot Study of Oral Rifaximin in Patients with Monoclonal Gammopathy
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03820817
Protocol IDs
Winship4480-18
NCI-2018-02106
IRB00106380
103.
Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03267888
Protocol IDs
RAD4106-17
NCI-2017-01485
IRB00097324
104.
Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02101944
Protocol IDs
9603
9603
NCI-2014-00643
2014C0091
NCI-9603
OSU-14031
14031
105.
PRISM: A Platform Protocol for the Treatment of Relapsed / Refractory Aggressive Non-Hodgkin's Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03527147
Protocol IDs
ACE-LY-111
NCI-2018-02392
D9820C00001
LYM 138
2017-004191-63
107.
NCORP Trial
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03269669
Protocol IDs
S1608
S1608
NCI-2017-00009
S1608
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
110.
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Cancer Type
Lymphoma, Multiple Myeloma, Unknown Primary
NCI ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
111.
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT03570892
Protocol IDs
CCTL019H2301
NCI-2018-02925
2016-002966-29
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.